Kevin Tan Sells 4,073 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) Stock

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) CFO Kevin Tan sold 4,073 shares of the stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $3.89, for a total value of $15,843.97. Following the completion of the transaction, the chief financial officer now owns 24,789 shares in the company, valued at approximately $96,429.21. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Solid Biosciences Price Performance

Shares of SLDB stock traded down $0.37 during midday trading on Monday, hitting $3.31. The company had a trading volume of 553,034 shares, compared to its average volume of 816,412. The stock has a market cap of $132.25 million, a price-to-earnings ratio of -1.09 and a beta of 2.05. The company's 50 day simple moving average is $4.88 and its 200 day simple moving average is $6.61. Solid Biosciences Inc. has a 52-week low of $3.28 and a 52-week high of $15.05.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.12). Analysts anticipate that Solid Biosciences Inc. will post -2.85 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in SLDB. Bank of New York Mellon Corp purchased a new stake in Solid Biosciences in the 2nd quarter valued at approximately $392,000. Rhumbline Advisers purchased a new stake in shares of Solid Biosciences in the second quarter valued at approximately $191,000. Acadian Asset Management LLC acquired a new position in Solid Biosciences during the second quarter worth $379,000. American Century Companies Inc. raised its position in Solid Biosciences by 39.9% in the second quarter. American Century Companies Inc. now owns 34,557 shares of the company's stock worth $196,000 after acquiring an additional 9,853 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Solid Biosciences by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company's stock valued at $402,000 after acquiring an additional 5,287 shares during the period. 81.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SLDB has been the subject of a number of research analyst reports. Citizens Jmp raised Solid Biosciences to a "strong-buy" rating in a report on Tuesday, December 10th. Wedbush started coverage on shares of Solid Biosciences in a research report on Friday, December 13th. They issued an "outperform" rating and a $16.00 target price on the stock. Truist Financial initiated coverage on shares of Solid Biosciences in a research report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $16.00 price objective on shares of Solid Biosciences in a report on Friday. Finally, JPMorgan Chase & Co. reduced their target price on Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating for the company in a report on Tuesday, November 12th. Nine investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $15.30.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.